Gravity Analytica

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

JAZZ 10.23.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-06

Name of Upcoming Event:Earnings Call

Full Press Release SEC Filings Our JAZZ Tweets

About Gravity Analytica

Recent Filings

DUBLIN,Oct. 23, 2024/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results onWednesday, November 6, 2024, after the close of theU.S.financial markets. Company management will host a live audio webcast at4:30 p.m. ET/9:30 p.m. GMTto discuss 2024 third quarter financial results and provide a business and financial update.

Audio webcast/conference call:U.S.Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are availablehere.Passcode: 5080203

Interested parties may access the live audio webcast via the Investors section of theJazz Pharmaceuticalswebsite athttps://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of theJazz Pharmaceuticalswebsite athttps://investor.jazzpharma.com/investors/events-presentations.

AboutJazz PharmaceuticalsJazz Pharmaceuticals plc(Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered inDublin, Irelandwith research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.

Contacts:

Investors:Andrea N. Flynn, Ph.D.Vice President, Head, Investor RelationsJazz Pharmaceuticals plcInvestorInfo@jazzpharma.comIreland +353 1 634 3211U.S.+1 650 496 2717

Media:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals plcCorporateAffairsMediaInfo@jazzpharma.comIreland +353 1 637 2141U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-third-quarter-financial-results-on-november-6-2024-302284892.html

SOURCEJazz Pharmaceuticals plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com